Can neuronal-surface autoantibodies disrupt synaptic signaling and cause cognitive dysfunction, while serum positivity alone is not diagnostic?

Neuronal-surface autoantibodies are biologically capable of causing reversible synaptic dysfunction and cognitive symptoms, but an antibody result must be interpreted within the full neurologic syndrome rather than treated as diagnostic in isolation.

Synaptic and cognitive effects

• GABA-A receptor antibodies can reduce synaptic receptor density and inhibitory postsynaptic currents; GABA-B receptor antibodies can functionally antagonize receptor signaling. These effects disturb excitation–inhibition balance and are associated with encephalopathy, limbic syndromes, and memory impairment.
• Patient-derived CASPR2 IgG provides translational support for a functional cognitive mechanism: it reduces synaptic AMPA-receptor availability, disrupts inhibitory synaptic organization, and decreases AMPA-mediated currents. In passive-transfer mice with blood–brain-barrier disruption, these changes accompanied impaired spontaneous alternation (a working-memory measure) without neuronal loss.
• Cognitive impairment in affected patients may therefore result from synaptic dysfunction rather than irreversible neurodegeneration alone, although seizures, encephalitis severity, structural injury, psychiatric manifestations, and sedating treatments can also contribute.

Diagnostic interpretation

• Serum neural-antibody positivity alone does not establish pathogenic autoimmune encephalitis. Diagnosis requires a compatible subacute neurologic or psychiatric phenotype, objective CNS evidence, and exclusion of plausible alternatives.
• Isolated serum findings can be false-positive or clinically irrelevant, especially when low-titer, phenotype-discordant, or obtained through broad testing in low-pretest-probability settings. For some unconfirmed isolated serum results, reported positive predictive value is as low as 5%.
• Paired serum–CSF testing is preferred: CSF is more sensitive for NMDAR and GFAP antibodies, whereas serum may be more sensitive for LGI1 and certain onconeural antibodies. Weak or discordant results warrant confirmation by a reference laboratory, tissue-based immunohistochemistry, or a second assay, integrated with CSF, MRI, EEG, and clinical findings.

Bottom line

• Neuronal-surface antibodies can directly impair synaptic transmission and plausibly cause cognitive dysfunction, but a serum-positive test is supportive evidence—not proof—of autoimmune encephalitis without clinical and paraclinical concordance.